Effect of the angiotensin II antagonist saralasin on plasma aldosterone concentration and on blood pressure before and during sodium depletion in normal subjects. 1979

E Agabiti-Rosei, and J J Brown, and W C Brown, and R Fraser, and P M Trust, and A F Lever, and J J Morton, and J I Robertson

The effect of the angiotensin II antagonist saralasin on plasma aldosterone, plasma angiotensin II and blood pressure was studied in six normal supine subjects both before and during sodium depletion. Before sodium depletion, infusion of saralasin produced no consistent changes; during sodium depletion, infusion of the angiotensin antagonist caused a fall in plasma aldosterone and an increase in plasma angiotensin II in each subject. It is concluded that angiotensin II plays a major part in stimulating aldosterone secretion during sodium depletion in man.

UI MeSH Term Description Entries
D008297 Male Males
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000450 Aldosterone A hormone secreted by the ADRENAL CORTEX that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium. Aldosterone, (+-)-Isomer,Aldosterone, (11 beta,17 alpha)-Isomer
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D012504 Saralasin An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION. 1-Sar-8-Ala Angiotensin II,1-Sarcosine-8-Alanine Angiotensin II,(Sar(1),Ala(8))ANGII,(Sar1,Val5,Ala8)Angiotensin II,Angiotensin II, Sar(1)-Ala(8)-,Angiotensin II, Sarcosyl(1)-Alanine(8)-,Sar-Arg-Val-Tyr-Val-His-Pro-Ala,Saralasin Acetate,Saralasin Acetate, Anhydrous,Saralasin Acetate, Hydrated,1 Sar 8 Ala Angiotensin II,1 Sarcosine 8 Alanine Angiotensin II,Angiotensin II, 1-Sar-8-Ala,Angiotensin II, 1-Sarcosine-8-Alanine,Anhydrous Saralasin Acetate,Hydrated Saralasin Acetate
D012964 Sodium A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23. Sodium Ion Level,Sodium-23,Ion Level, Sodium,Level, Sodium Ion,Sodium 23

Related Publications

E Agabiti-Rosei, and J J Brown, and W C Brown, and R Fraser, and P M Trust, and A F Lever, and J J Morton, and J I Robertson
October 1980, European journal of clinical pharmacology,
E Agabiti-Rosei, and J J Brown, and W C Brown, and R Fraser, and P M Trust, and A F Lever, and J J Morton, and J I Robertson
May 1980, Circulation,
E Agabiti-Rosei, and J J Brown, and W C Brown, and R Fraser, and P M Trust, and A F Lever, and J J Morton, and J I Robertson
February 1978, Clinical nephrology,
E Agabiti-Rosei, and J J Brown, and W C Brown, and R Fraser, and P M Trust, and A F Lever, and J J Morton, and J I Robertson
May 1975, Japanese circulation journal,
E Agabiti-Rosei, and J J Brown, and W C Brown, and R Fraser, and P M Trust, and A F Lever, and J J Morton, and J I Robertson
August 1989, Hypertension (Dallas, Tex. : 1979),
E Agabiti-Rosei, and J J Brown, and W C Brown, and R Fraser, and P M Trust, and A F Lever, and J J Morton, and J I Robertson
November 1979, Nihon Jinzo Gakkai shi,
E Agabiti-Rosei, and J J Brown, and W C Brown, and R Fraser, and P M Trust, and A F Lever, and J J Morton, and J I Robertson
October 1979, Endocrinologia japonica,
E Agabiti-Rosei, and J J Brown, and W C Brown, and R Fraser, and P M Trust, and A F Lever, and J J Morton, and J I Robertson
December 1976, Schweizerische medizinische Wochenschrift,
E Agabiti-Rosei, and J J Brown, and W C Brown, and R Fraser, and P M Trust, and A F Lever, and J J Morton, and J I Robertson
January 1984, Japanese heart journal,
E Agabiti-Rosei, and J J Brown, and W C Brown, and R Fraser, and P M Trust, and A F Lever, and J J Morton, and J I Robertson
January 1979, Arzneimittel-Forschung,
Copied contents to your clipboard!